主要股东Ansbert Gadicke在11月17日出售了57 061股狼人治疗药品,其中一部分是内幕出售总额超过70万股的股份。 Major shareholder Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics on Nov. 17, part of insider selling totaling over 700,000 shares.

主要股东Ansbert Gadicke于2025年11月17日出售了57 061股狼人治疗学(HOWL),每股0.95美元,这是从11月3日至17日内幕销售总额超过70万股的较大趋势的一部分。 Major shareholder Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics (HOWL) on November 17, 2025, at $0.95 each, part of a larger trend of insider sales totaling over 700,000 shares from November 3 to 17. 这些交易是向证交会提出的,表明盖迪克的所有权下降了1.03%,使他拥有5 481 539股股份。 The transactions, filed with the SEC, reflect a 1.03% drop in Gadicke’s ownership, leaving him with 5,481,539 shares. 一个单独实体,2014年Bioventures L.P. Mpm也在同一期间出售股票。 A separate entity, Bioventures 2014 L.P. Mpm, also sold shares during the same period. 据该公司报告,在11月4日,每股季度损失0.36美元,估计略微增加。 The company reported a quarterly loss of $0.36 per share on November 4, slightly beating estimates. 该股票于11月17日以92美元关闭,市场上限为4 463万美元。 The stock closed at $0.92 on November 17 with a market cap of $44.63 million. 分析师有好坏参半的评级,导致协商一致的“机动买”和8.00美元的价格目标。 Analysts have mixed ratings, resulting in a consensus "Moderate Buy" and a $8.00 price target.